Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma

E-ISSN： 1537-2995|55|11|2770-2770

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.11, 2015-11, pp. : 2770-2770

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

INTERNAL MEDICINE JOURNAL, Vol. 48, Iss. 2, 2018-02 ,pp. : 210-220

John Wiley & Sons Inc

Access to resources Recommend Favorite

An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab

TRANSFUSION, Vol. 55, Iss. 9, 2015-09 ,pp. : 2292-2293

John Wiley & Sons Inc

Access to resources Recommend Favorite

An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab

TRANSFUSION, Vol. 41-1132, Iss. 9, 2015-09 ,pp. : 2292-2293

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

Oncology Research and Treatment, Vol. 39, Iss. 6, 2016-05 ,pp. : 384-387

Karger

Access to resources Recommend Favorite

New Recurrent Chromosome Alterations in Patients with Multiple Myeloma and Plasma Cell Leukemia

Cytogenetic and Genome Research, Vol. 134, Iss. 4, 2011-07 ,pp. : 249-259

Karger

Access to resources Recommend Favorite